SEARCH:
Signup to create an account
test
Lone Star Opposes SWS Group's Merger Plans

SWS Group Inc. (NYSE: SWS), a diversified financial services holding company, recently announced a merger agreement with Hilltop Holdings Inc. (NYSE: HTH) in a cash and stock transaction amounting to 0.2469 shares of HTH and $1.94 in cash for each share of SWS.

test
JANA Partners Tightens the Leash on PetSmart

PetSmart Inc. (NASDAQ: PETM), a leading retailer of pets and pet-related goods and services, recently hired JPMorgan Chase to analyze the possibility of a leveraged share buyback, according to Reuters reports.


test
HighTech Set To Disrupt the BioTech Industry

In a new world of high tech discoveries, Silicon Valley is creating advances that are now being used to revolutionize the biotech industry.

Recent 8K Filings
GRANT PARK FUTURES FUND LIMITED PARTNERSHIP
FLEXIBLE SOLUTIONS INTERNATIONAL INC
SANDISK CORP
BIOSPECIFICS TECHNOLOGIES CORP
TRANSGLOBE ENERGY CORP
DIGITAL DEVELOPMENT GROUP CORP
MCEWEN MINING INC.
MTR GAMING GROUP INC
CESCA THERAPEUTICS INC.

Recent Insider Filings
ALIGN TECHNOLOGY INC (GRAHAM JOHN PATRICK)
OPKO HEALTH, INC. (FROST PHILLIP MD ET AL)
PIONEER NATURAL RESOURCES CO (THOMPSON J KENNETH)
KIMBALL INTERNATIONAL INC (SCHNEIDER ROBERT F)
EMISPHERE TECHNOLOGIES INC (RACHESKY MARK H MD)
OURPETS CO (TSENGAS KONSTANTINE S)
ALLIANCE ONE INTERNATIONAL, INC. (HINES JOHN M)
LIQTECH INTERNATIONAL INC (VERNON MARK)
PARTNERRE LTD (SAUTTER REMY)



Executive Interview
Quantum Energy, Inc. (OTC: QEGY)
In this episode we speak with Mr. Russell Smith, EVP of Public Affairs for Quantum Energy, about the company's plans to build 21st Century Energy Centers in the Bakken oil fields.


Executive Interview
Theralase Technologies (OTC: TLTFF)
In this episode we will be talking to Mr. Roger Dumoulin-White, President & CEO of Theralase Technologies. Theralase designs, manufactures and markets patented, super-pulsed laser technology used in eliminating pain and destroying cancer.


Executive Interview
Galectin Therapeutics (NASDAQ: GALT)
In this SECFilings.com Executive Interview we speak with Mr. Jim Czirr, Executive Chairman of Galectin Therapeutics.